apc conjugated anti cd163  (Elabscience Biotechnology)

Journal: Journal of Nanobiotechnology

Article Title: Determining M2 macrophages content for the anti-tumor effects of metal-organic framework-encapsulated pazopanib nanoparticles in breast cancer

doi: 10.1186/s12951-024-02694-z

Figure Lengend Snippet: Validation of decreased M2-like macrophages following PAZ@Fe-MOF treatment. ( A ) Representative immunostaining images of Mrc1 and Cd163 on mice specimens. Scale bars are indicated. ( B ) Protein levels of Mrc1 and Cd163 were quantified in mice specimens with different treatment. ( C-D ) Flow cytometry indicated the effects of PAZ@Fe-MOF on the tumor-infiltrating Cd163 + Mrc1 + cells. ( E-F ) Infiltration of M2-like macrophages in human breast cancer cells MDA-MB-231 treated with the indicated conditions. ( G ) PAZ@Fe-MOF-RhB nanoagents could be absorbed by IL-4-stimulated RAW264.7 cells. ( H-I ) The mean fluorescence intensity was quantified. ( J ) ER was labeled by the ER-tracker. In IL-4-stimulated RAW264.7 cells, the co-localization of PAZ@Fe-MOF with ER were observed with confocal microscopy. *: p -value < 0.05, **: p -value < 0.01

Article Snippet: Cell pellets were incubated with APC anti-mouse Cd163 Monoclonal Antibody (eBioscience™, TNKUPJ) and FITC anti-mouse Mrc1 (Biolegend, 068C2) antibody on ice, in the dark, for 20 min.

Techniques: Immunostaining, Flow Cytometry, Fluorescence, Labeling, Confocal Microscopy